Arvinas Inc. (ARVN) and Pfizer (PFE) Announce PROTAC Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breas
Go back to Arvinas Inc. (ARVN) and Pfizer (PFE) Announce PROTAC Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breas| (NASDAQ: ARVN) | Delayed: 8.31 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.31 | 52 Week High | $ | |||
| Open | $8.31 | 52 Week Low | $ | |||
| Day High | $8.31 | P/E | N/A | |||
| Day Low | $8.31 | EPS | $ | |||
| Volume | 1 | |||||
| Pfizer Inc. (NYSE: PFE) | Delayed: 27.64 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.64 | 52 Week High | $37.39 | |||
| Open | $27.64 | 52 Week Low | $28.25 | |||
| Day High | $27.64 | P/E | 16.75 | |||
| Day Low | $27.64 | EPS | $1.65 | |||
| Volume | 69,496 | |||||

